Angela Shaulov Kask

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma

Ramya Ramaswami, Angela Shaulov Kask, Leonard D’Amico, Manoj Menon et autres

Background CD4+ T-cell lymphocytopenia and immune dysfunction are factors that drive the onset and persistence of Kaposi sarcoma (KS) in people with (PWH) and without HIV. Standard chemotherapy agents for KS can contribute to increasing CD4+ T cell lymphocytopenia. IL-7 is a …

us (code pays fourni par la source)

Supplementary Figure S2 from A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Randy F. Sweis, Gurkamal Chatta, Rohit K. Jain, Helen Moon et autres

Kaplan-Meier Curve for Overall Survival - All Randomized Subjects.

Supplementary Figure S4 from A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Randy F. Sweis, Gurkamal Chatta, Rohit K. Jain, Helen Moon et autres

Pharmacodynamics showing fold-change from baseline of % of T lymphocyte memory subsets for (A,C) CD4+ T cells and (B,D) CD8+ T cells. Tscm lymphocyte subset the most highly significantly expanded T cell subset for both CD4+ and CD8+ T cells and seen …

Supplementary Table S1 from A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Randy F. Sweis, Gurkamal Chatta, Rohit K. Jain, Helen Moon et autres

Representativeness of Study Participants

Supplementary Table S2 from A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Randy F. Sweis, Gurkamal Chatta, Rohit K. Jain, Helen Moon et autres

Clinical outcomes

Supplementary Figure S1 from A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Randy F. Sweis, Gurkamal Chatta, Rohit K. Jain, Helen Moon et autres

Kaplan-Meier Curve for Progression Free Survival as measured by RECIST v1.1 - All Randomized Subjects.

Supplementary Figure S5 from A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Randy F. Sweis, Gurkamal Chatta, Rohit K. Jain, Helen Moon et autres

Cytokine changes between C1D1 and C2D1 in the experimental arm.

Supplementary Figure S3 from A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Randy F. Sweis, Gurkamal Chatta, Rohit K. Jain, Helen Moon et autres

Pharmacodynamics of CD4+ (A) and CD8+ (B) T cell populations in the experimental arm showing fold-change from baseline of % of T lymphocyte subsets. Significant differences were most observed in the CD4+ effector memory T cell population.

Data from A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Randy F. Sweis, Gurkamal Chatta, Rohit K. Jain, Helen Moon et autres

AbstractPurpose: Advanced urothelial cancer generally has high mortality despite modern anti–PD-1/L1 antibody–based combinations. Augmenting checkpoint inhibitor–mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (Cancer Immunotherapy Trials Network-14) in 47 patients to explore whether …

Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma

Jian Campian, Stuart A. Grossman, Angela Shaulov Kask, Samuel Kosydar et autres

Abstract Background High-grade gliomas (HGG) have a poor prognosis despite aggressive treatment. Severe, persistent lymphopenia occurring in HGG patients after concurrent chemoradiation is associated with worse survival. NT-I7, a long-acting interleukin-7 analog, has been shown to increase CD4 and CD8 counts in …

us (code pays fourni par la source)

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Randy F. Sweis, Gurkamal Chatta, Rohit K. Jain, Helen Moon et autres

PURPOSE: Advanced urothelial cancer generally has high mortality despite modern anti-PD-1/L1 antibody-based combinations. Augmenting checkpoint inhibitor-mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (Cancer Immunotherapy Trials Network-14) in 47 patients to explore whether …

us, cn (code pays fourni par la source)

Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma

Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Vanessa Eulo et autres

PURPOSE Cancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort. METHODS In this multicenter phase I trial, we enrolled participants with HIV-associated KS on …

us (code pays fourni par la source)